📊 ADCT Key Takeaways
Investment Thesis
ADC Therapeutics is in severe financial distress with negative stockholders' equity of -$185.8M, indicating liabilities exceed assets by a significant margin. The company is burning cash at an alarming rate (-$141.2M operating cash flow) while revenues of $81.4M cannot offset massive R&D and operational expenses typical of early-stage pharma. Without a path to profitability or significant capital infusion, the company faces existential solvency risk.
ADCT Strengths
- Strong short-term liquidity with current ratio of 4.37x and $261.3M in cash providing near-term runway
- Revenue showing positive growth of 14.9% YoY suggests product traction
- Recent insider Form 4 filings indicate management is still engaged
ADCT Risks
- Negative stockholders' equity of -$185.8M represents balance sheet insolvency and extreme financial distress
- Massive cash burn rate of -$141.2M annually with only $261.3M in cash implies less than 2 years of runway at current burn
- Operating margin of -149.3% and net margin of -175.3% show severe operating losses with no clear path to breakeven
- Liabilities ($509.0M) exceed total assets ($323.1M) by $185.8M, indicating potential covenant violations or restructuring risk
- Interest coverage ratio of -7.5x shows inability to service debt from operations
Key Metrics to Watch
- Monthly cash burn rate and updated liquidity runway estimate
- Revenue growth sustainability and gross margin realization when available
- Operating expense reduction progress and timeline to breakeven
ADCT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.37x current ratio provides a solid financial cushion.
ADCT Profitability Ratios
ADCT vs Healthcare Sector
How ADC Therapeutics SA compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
ADCT Balance Sheet & Liquidity
ADCT 5-Year Financial Trend
5-Year Trend Summary: ADC Therapeutics SA's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.62 indicates the company is currently unprofitable.
ADCT Growth Metrics (YoY)
ADCT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $15.8M | -$41.0M | $-0.30 |
| Q2 2025 | $17.0M | -$36.5M | $-0.38 |
| Q1 2025 | $17.4M | -$38.6M | $-0.36 |
| Q3 2024 | $14.3M | -$44.0M | $-0.42 |
| Q2 2024 | $17.0M | -$36.5M | $-0.38 |
| Q1 2024 | $17.8M | -$46.6M | $-0.56 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ADCT Capital Allocation
ADCT SEC Filings
Access official SEC EDGAR filings for ADC Therapeutics SA (CIK: 0001771910)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADCT
What is the AI rating for ADCT?
ADC Therapeutics SA (ADCT) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADCT's key strengths?
Strong short-term liquidity with current ratio of 4.37x and $261.3M in cash providing near-term runway. Revenue showing positive growth of 14.9% YoY suggests product traction.
What are the risks of investing in ADCT?
Negative stockholders' equity of -$185.8M represents balance sheet insolvency and extreme financial distress. Massive cash burn rate of -$141.2M annually with only $261.3M in cash implies less than 2 years of runway at current burn.
What is ADCT's revenue and growth?
ADC Therapeutics SA reported revenue of $81.4M.
Does ADCT pay dividends?
ADC Therapeutics SA does not currently pay dividends.
Where can I find ADCT SEC filings?
Official SEC filings for ADC Therapeutics SA (CIK: 0001771910) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADCT's EPS?
ADC Therapeutics SA has a diluted EPS of $-1.12.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.